https://www.selleckchem.com/pr....oducts/Vorinostat-sa
Patients with atopic dermatitis (AD) experience burdensome symptoms and impaired quality of life (QoL). The objective of this study was to investigate the effects of topical AD therapies on disease control, physician and patient treatment satisfaction, and QoL in a real-world setting. This was a retrospective, point-in-time study of physician-completed medical records and patient surveys drawn from two Adelphi AD Disease Specific Programmes™ (1. adults ≥ 18years old; 2. pediatrics ≤ 17years old) in the USA. Eligible physicians c
Like
Comment
Share
